Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

Comorbidities do not significantly impact treatment retention rates among patients with inflammatory RMDs who switch from originator to biosimilar adalimumab.

Whereas 89.5% of new prescriptions for disease-modifying anti-rheumatic drugs (DMARDs) in 2000 were for old-line agents, by ...

with adalimumab becoming the most commonly used b/tsDMARD. Researchers performed a serial cross-sectional study using ...

Treatment with CZP vs ADA may offer more consistent efficacy when used among patients with RA who have elevated RF levels.

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Cyltezo is a prescription drug used to treat certain inflammatory conditions. Learn about the side effects it can cause and how to manage them.

A recent post hoc analysis of the EXXELERATE study revealed that certolizumab pegol (CZP) sustained drug concentration and ...